Researchers from the University of Oslo (UiO), Akershus University Hospital (Ahus), and an extensive network of international collaborators have published a pivotal expert review in the esteemed journal Nature Aging. This groundbreaking paper represents a significant global effort, uniting over 25 leading scientists, including seasoned clinicians and renowned experts in aging biology and metabolism. The collective focus of this multidisciplinary team is the molecule nicotinamide adenine dinucleotide (NAD+), with the overarching aim of elucidating its potential to promote healthier aging and offer protective benefits against debilitating neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. The review consolidates years of research and presents a clear scientific roadmap for future investigations and clinical applications.
The Central Role of NAD+ in Cellular Health and Aging
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells, playing an indispensable role in a vast array of cellular processes. It is often described as the "fuel regulator" of the cell, directly influencing energy production through its involvement in metabolic pathways like glycolysis and the citric acid cycle. Beyond energy generation, NAD+ is a critical component in DNA repair mechanisms, acting as a substrate for enzymes such as PARPs (poly(ADP-ribose) polymerases) that are essential for maintaining genomic integrity. Furthermore, NAD+ is a key player in cell signaling and regulates the activity of sirtuins, a class of proteins linked to longevity and stress resistance.
However, a critical aspect of aging is the natural and progressive decline in NAD+ levels. This decline begins in early adulthood and continues throughout life. By the time individuals reach their 60s and 70s, NAD+ levels can be significantly lower than those of younger adults. This depletion is not merely a passive consequence of aging; it is increasingly recognized as a driving factor behind many age-related functional impairments. Scientific evidence links reduced NAD+ levels to a host of detrimental effects, including cognitive decline, characterized by memory problems and reduced learning capacity; diminished muscle strength and endurance, contributing to sarcopenia; and a heightened susceptibility to various age-related diseases, including cardiovascular disorders, metabolic syndrome, and neurodegenerative conditions. The pervasive nature of this decline underscores the importance of understanding and potentially mitigating it to foster healthier longevity.
Promising Avenues: NAD+ Precursors and Early Clinical Findings
The Nature Aging review meticulously examines decades of research, spanning from foundational laboratory studies to emerging clinical trials, all aimed at identifying effective strategies to boost NAD+ levels. A primary focus of these investigations involves the use of vitamin-like compounds known as NAD+ precursors. Among the most extensively studied are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These molecules serve as building blocks for NAD+, and their administration has shown the potential to increase intracellular NAD+ concentrations in various tissues.
Early findings from clinical studies investigating NR and NMN supplementation have been encouraging. Some trials have reported observable improvements in cognitive function, including enhanced memory recall and processing speed, in older adults. Furthermore, studies have indicated positive effects on physical performance, with participants experiencing improvements in muscle strength and endurance. Metabolic health markers have also shown promise, with some research suggesting benefits for glucose metabolism and insulin sensitivity. These preliminary results have fueled optimism within the scientific community and among the public regarding the therapeutic potential of NAD+ augmentation.
However, the researchers involved in the review emphatically stress that while these early findings are promising, they represent just the tip of the iceberg. The current body of evidence, though growing, is largely based on relatively small-scale studies with limited durations. To definitively confirm the efficacy and long-term benefits of NAD+ precursor supplementation across a spectrum of age-related diseases, larger, more robust, and longer-term clinical trials are imperative. These studies must be designed to rigorously assess outcomes in diverse patient populations and across different disease states.
Navigating the Hype: Rising Interest and Scientific Scrutiny
The publication of this comprehensive review coincides with a period of escalating interest in NAD+ and its potential therapeutic applications, both from the scientific community and the general public. A burgeoning global market for NAD+ supplements has emerged, driven by the compelling narrative of anti-aging and disease prevention. This rapid expansion has, however, also given rise to a significant amount of debate and, at times, confusion. Questions abound regarding the optimal dosage, the long-term safety profiles of various supplementation strategies, and the extent to which findings from animal models can be reliably extrapolated to human physiology.
Dr. Jianying Zhang, one of the lead authors of the review, articulates this critical juncture: "Fine-tuning NAD+ metabolism holds promise for delaying age-related health decline as well as disease such as premature ageing diseases. But to truly unlock its potential, we need to better understand the right doses, long-term safety, and interindividual variability in response to NAD+ augmentation strategies." This statement highlights the crucial need for rigorous scientific inquiry to move beyond anecdotal evidence and speculative claims.
Dr. Evandro Fei Fang-Stavem, the senior author and head of the Fang Lab at UiO and Ahus, further emphasizes the timely nature of their work: "This is why we believe the timing is right to share an expert opinion. NAD+ is fundamental to life, yet there is still confusion and noise in the field about which supplements work best and how they should be used. Our article consolidates the evidence and provides a scientific roadmap to guide both ongoing research and future clinical use." The review’s intention is to cut through the noise, providing a scientifically grounded perspective that can inform both researchers and the public.
Professor Torbjørn Omland, MD, PhD, MPH, Deputy Head of the Institute of Clinical Medicine and a co-author, underscores the review’s educational value: "There is a knowledge gap on NAD+ and its clinical effects to basic researchers and clinicians, and this review paper provides the latest expert opinion to those who are interested in and are working in the field NAD+ research. This review will also provide relevant information to many NAD+-based clinical trials across a wide spectrum of clinical conditions, including neurological and cardiovascular disease." The review aims to bridge this knowledge gap, equipping a broader audience with the scientific understanding necessary to engage with NAD+ research and its clinical implications.
A Call for Rigorous Research and Global Collaboration
The authors of the Nature Aging review are unified in their call for continued and intensified research efforts. While NAD+-based supplements and therapies are generating considerable excitement and are undergoing widespread investigation, they emphasize that stronger collaboration among researchers and more rigorous, well-designed clinical testing are absolutely essential. These steps are not merely desirable but critical for translating promising early findings into safe, effective, and widely accessible treatments for aging and its associated diseases.
The implications of this research extend far beyond individual health. A deeper understanding of NAD+ metabolism and the development of effective interventions could have profound societal impacts. By potentially delaying the onset of age-related diseases and improving overall healthspan, these advancements could reduce the burden on healthcare systems, enhance the quality of life for aging populations, and allow individuals to remain active and productive members of society for longer. This could reshape economic landscapes, redefine retirement, and fundamentally alter our societal approach to aging.
Chronology of NAD+ Research and Clinical Interest
The scientific journey into NAD+ and its role in aging has been a gradual but accelerating process.
- Mid-20th Century: Early biochemical studies establish the existence and fundamental role of NAD+ in cellular respiration and metabolism.
- Late 20th Century – Early 21st Century: The discovery of sirtuins and their dependence on NAD+ for activity ignites renewed interest in the molecule’s link to longevity and stress resistance. Research begins to explore the decline of NAD+ with age.
- Early 2000s: Identification of NAD+ precursors like NR and NMN and initial investigations into their ability to replenish NAD+ levels.
- 2010s: A surge in preclinical studies demonstrating the benefits of NAD+ boosting in animal models for various age-related conditions, including metabolic disorders and neurodegeneration. Initial small-scale human trials commence.
- Late 2010s – Present: A significant increase in the number of clinical trials exploring NAD+ precursors for a range of human health conditions. The emergence of a substantial direct-to-consumer supplement market for NR and NMN. Publication of comprehensive reviews like the one in Nature Aging, aiming to synthesize existing knowledge and guide future research.
This timeline illustrates a transition from basic biochemical understanding to targeted therapeutic exploration, driven by increasing evidence of NAD+’s central role in aging biology.
Supporting Data and Scientific Context
The decline in NAD+ levels with age is not a theoretical construct but a quantifiable biological phenomenon. Studies have shown that NAD+ levels in the liver can decrease by up to 50% between the ages of 50 and 70. Similar age-related declines have been observed in muscle tissue and the brain. This depletion has been correlated with reduced mitochondrial function, increased oxidative stress, and impaired DNA repair capacity – all hallmarks of cellular aging.
For instance, research published in journals like Cell Metabolism and Science has provided robust evidence linking NAD+ depletion to impaired mitochondrial function. When NAD+ levels are low, mitochondria, the powerhouses of the cell, become less efficient at generating ATP (adenosine triphosphate), the primary energy currency of the cell. This energy deficit can manifest as fatigue, reduced physical capacity, and impaired organ function.
In the context of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, the role of NAD+ is particularly poignant. Studies suggest that reduced NAD+ levels in neurons can compromise their ability to cope with cellular stress, clear protein aggregates (like amyloid plaques and tau tangles in Alzheimer’s), and maintain synaptic function, all of which are critical for cognitive health. The review in Nature Aging likely synthesizes data from numerous studies that have investigated these connections, providing a unified perspective on the molecular mechanisms at play.
International Contributions and Future Directions
The review’s international scope highlights the global nature of the scientific endeavor to understand and combat age-related decline. Beyond the Norwegian institutions, the research team includes affiliations with prominent research centers worldwide, such as the University of Copenhagen (Denmark), Chiba University (Japan), Harvard Medical School (USA), and the Buck Institute for Research on Aging (USA). This collaborative approach ensures a broad exchange of knowledge, diverse perspectives, and a shared commitment to advancing the field.
The Norwegian contributors represent a strong contingent in this international effort: Sofie Lautrup (UiO and Ahus), Hilde Loge Nilsen (OUS – Oslo University Hospital), Leiv Otto Watne (Ahus and UiO), Geir Selbæk (UiO and Norwegian National Centre for Ageing and Health), Mathias Ziegler (UiB – University of Bergen), Ole-Bjørn Tysnes (UiB), and Charalampos Tzoulis (UiB). Their involvement underscores Norway’s significant contribution to cutting-edge aging research.
The future directions outlined in the review are clear:
- Larger, Longer Clinical Trials: To move beyond observational data and early indicators, robust clinical trials with larger participant numbers and extended follow-up periods are crucial. These trials should focus on specific age-related diseases and endpoints.
- Dose-Finding and Safety Studies: Determining the optimal dosage of NAD+ precursors for various applications and thoroughly assessing their long-term safety profile in humans is paramount.
- Understanding Interindividual Variability: Recognizing that individuals respond differently to interventions, research must explore the genetic, lifestyle, and environmental factors that influence NAD+ metabolism and response to supplementation.
- Mechanism-Based Research: Continuing to unravel the precise molecular pathways through which NAD+ influences cellular health and disease is vital for developing targeted and effective therapies.
- Development of Biomarkers: Identifying reliable biomarkers to track NAD+ levels and the efficacy of interventions will be essential for guiding clinical practice and research.
The publication in Nature Aging serves as a critical milestone, consolidating current knowledge and providing a unified vision for the future of NAD+ research in the pursuit of healthier aging and the prevention of debilitating diseases. The collective expertise assembled for this review offers a powerful testament to the global commitment to tackling the complex challenges of aging.
